230 related articles for article (PubMed ID: 9601501)
1. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
4. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.
Martino TA; Petric M; Weingartl H; Bergelson JM; Opavsky MA; Richardson CD; Modlin JF; Finberg RW; Kain KC; Willis N; Gauntt CJ; Liu PP
Virology; 2000 May; 271(1):99-108. PubMed ID: 10814575
[TBL] [Abstract][Full Text] [Related]
5. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.
Shafren DR; Dorahy DJ; Thorne RF; Kinoshita T; Barry RD; Burns GF
J Immunol; 1998 Mar; 160(5):2318-23. PubMed ID: 9498772
[TBL] [Abstract][Full Text] [Related]
6. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
7. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.
Pinkert S; Westermann D; Wang X; Klingel K; Dörner A; Savvatis K; Grössl T; Krohn S; Tschöpe C; Zeichhardt H; Kotsch K; Weitmann K; Hoffmann W; Schultheiss HP; Spiller OB; Poller W; Fechner H
Circulation; 2009 Dec; 120(23):2358-66. PubMed ID: 19933937
[TBL] [Abstract][Full Text] [Related]
10. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
11. Decay-accelerating factor (CD55) promotes CD1d expression and Vgamma4+ T-cell activation in coxsackievirus B3-induced myocarditis.
Huber S; Song WC; Sartini D
Viral Immunol; 2006; 19(2):156-66. PubMed ID: 16817758
[TBL] [Abstract][Full Text] [Related]
12. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.
Spiller OB; Goodfellow IG; Evans DJ; Almond JW; Morgan BP
J Infect Dis; 2000 Jan; 181(1):340-3. PubMed ID: 10608785
[TBL] [Abstract][Full Text] [Related]
13. Coxsackievirus-B3-induced myocarditis: virus receptor antibodies modulate myocarditis.
Weller AH; Simpson K; Herzum M; Van Houten N; Huber SA
J Immunol; 1989 Sep; 143(6):1843-50. PubMed ID: 2550544
[TBL] [Abstract][Full Text] [Related]
14. Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor.
Myers SE; Brewer L; Shaw DP; Greene WH; Love BC; Hering B; Spiller OB; Njenga MK
Xenotransplantation; 2004 Nov; 11(6):536-46. PubMed ID: 15479464
[TBL] [Abstract][Full Text] [Related]
15. Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors.
Rezaikin AV; Novoselov AV; Sergeev AG; Fadeyev FA; Lebedev SV
Virus Res; 2009 Oct; 145(1):74-9. PubMed ID: 19540285
[TBL] [Abstract][Full Text] [Related]
16. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
17. Experimental SSM-CVB3 infection in macaques.
Han T; He W; Song D; Zhao K; Wu C; Gao F; Lu H; Gai X; Wang X; Li F; Ji C; Lin X
Exp Mol Pathol; 2012 Feb; 92(1):131-9. PubMed ID: 22079478
[TBL] [Abstract][Full Text] [Related]
18. Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells.
Chung SK; Kim JY; Kim IB; Park SI; Paek KH; Nam JH
Virology; 2005 Mar; 333(1):31-40. PubMed ID: 15708590
[TBL] [Abstract][Full Text] [Related]
19. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
[TBL] [Abstract][Full Text] [Related]
20. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
